Table 2.
Univariate and Multivariate Analysis of the Training Cohort for OS and RFS
| OS | RFS | |||||
|---|---|---|---|---|---|---|
| Variables | HR | 95% CI | P value | HR | 95% CI | P value |
| Univariate | ||||||
| Sex (Female/Male) | 1.404 | 0.869–2.268 | 0.165 | 1.663 | 1.098–2.519 | 0.016 |
| HBsAg (Negative/Positive) | 0.872 | 0.534–1.424 | 0.584 | 1.269 | 0.802–2.008 | 0.309 |
| Age (≤60/>60, y) | 1.295 | 0.926–1.811 | 0.131 | 1.168 | 0.880–1.550 | 0.281 |
| PLT (≤100/>100, x10^9/L) | 0.877 | 0.592–1.299 | 0.514 | 0.832 | 0.602–1.150 | 0.265 |
| TB (≥34.2/<34.2, μmol/L) | 1.915 | 0.611–6.009 | 0.265 | 1.262 | 0.404–3.943 | 0.689 |
| ALB (<40/≥40, g/L) | 1.302 | 0.934–1.814 | 0.120 | 1.674 | 1.278–2.191 | <0.001 |
| ALT (>50/≤50, IU/L) | 1.320 | 0.932–1.869 | 0.118 | 1.495 | 1.125–1.987 | 0.006 |
| AST (>40/≤40, IU/L) | 1.883 | 1.376–2.577 | <0.001 | 1.675 | 1.288–2.178 | <0.001 |
| GGT (>60/≤60, IU/L) | 1.910 | 1.389–2.627 | <0.001 | 1.668 | 1.286–2.163 | <0.001 |
| LDH (>225/≤225, IU/L) | 2.495 | 1.783–3.492 | <0.001 | 1.930 | 1.437–2.591 | <0.001 |
| ALP (>130/≤130, U/L) | 2.273 | 1.540–3.353 | <0.001 | 1.696 | 1.177–2.445 | 0.005 |
| HBV-DNA (≤2000/>2000, IU/mL) | 1.688 | 1.232–2.312 | 0.001 | 1.495 | 1.154–1.936 | 0.002 |
| AFP (>400/≤400, μg/L) | 1.899 | 1.387–2.598 | <0.001 | 1.367 | 1.046–1.787 | 0.022 |
| CEA (≤10/>10, μg/L) | 0.827 | 0.116–5.907 | 0.850 | 1.057 | 0.263–4.253 | 0.938 |
| CA199 (>39/≤39, μg/L) | 1.238 | 0.836–1.834 | 0.286 | 1.307 | 0.943–1.810 | 0.107 |
| APRI (≤0.9/>0.9) | 1.910 | 1.369–2.663 | <0.001 | 1.821 | 1.374–2.413 | <0.001 |
| Blood loss (≥400/<400, mL) | 2.388 | 1.731–3.294 | <0.001 | 1.733 | 1.310–2.292 | <0.001 |
| Tumor number (Single/Multiple) | 2.903 | 1.479–5.697 | 0.002 | 2.616 | 1.383–4.946 | 0.003 |
| Tumor size (>5/≤5, cm) | 3.151 | 2.288–4.340 | <0.001 | 1.934 | 1.493–2.505 | <0.001 |
| MVI (No/Yes) | 3.021 | 2.209–4.132 | <0.001 | 1.949 | 1.491–2.549 | <0.001 |
| Satellite lesions (No/Yes) | 2.159 | 1.571–2.967 | <0.001 | 1.650 | 1.255–2.171 | <0.001 |
| Livers cirrhosis (No/Yes) | 1.410 | 1.019–1.950 | 0.038 | 1.545 | 1.180–2.024 | 0.002 |
| Edmondson-Steiner grade (I+II/III+IV) | 1.900 | 1.211–2.982 | 0.005 | 1.294 | 0.932–1.798 | 0.124 |
| Child-Pugh (A/B) | 0.708 | 0.226–2.221 | 0.554 | 0.632 | 0.235–1.700 | 0.364 |
| Multivariate | ||||||
| APRI (≤0.9/>0.9) | 1.667 | 1.096–2.536 | 0.017 | 1.535 | 1.093–2.156 | 0.013 |
| Blood loss (≥400/<400, mL) | 1.671 | 1.178–2.370 | 0.004 | 1.419 | 1.044–1.928 | 0.025 |
| Tumor number (Single/Multiple) | 3.957 | 1.904–8.222 | <0.001 | 2.389 | 1.219–4.681 | 0.011 |
| Tumor size (>5/≤5, cm) | 2.637 | 1.756–3.961 | <0.001 | 1.754 | 1.270–2.422 | 0.001 |
| MVI (No/Yes) | 1.905 | 1.342–2.705 | <0.001 | 1.571 | 1.169–2.112 | 0.003 |
| Satellite lesions (No/Yes) | 1.645 | 1.162–2.329 | 0.005 | 1.370 | 1.019–1.840 | 0.037 |
| Livers cirrhosis (No/Yes) | 1.553 | 1.072–2.249 | 0.020 | 1.485 | 1.091–2.021 | 0.012 |
| Sex (Female/Male) | 1.583 | 1.024–2.449 | 0.039 | |||
| ALB (<40/≥40, g/L) | 1.445 | 1.085–1.925 | 0.012 | |||
Note: P<0.05 was defined as statistical significance.
Abbreviations: OS, overall survival; RFS, recurrence-free survival; HBsAg, hepatitis B surface antigen; PLT, platelets; TB, total bilirubin; ALB, albumin; ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; HBV-DNA, hepatitis B virus deoxyribonucleic acid; AFP, a-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19–9; APRI, aspartate aminotransferase-to-platelet ratio index; MVI, microvascular invasion.